IRVINE, Calif., Aug. 14, 2007 (PRIME NEWSWIRE) -- "For companies that have created potentially life-changing, breakthrough technologies in the health care space accolades from major publications like Business Week are welcome vehicles in the pathway to exposure and understanding," stated SmallCap Sentinel analyst D.R. Clark. "It's an entirely different event when your peer group -- pharmaceutical executives -- calls your angiogenesis therapy 'one of the seven top therapies and technologies vying to deliver the next decade's breakthroughs and blockbusters.'"
"A recent Pharmaceutical Executive magazine article profiles new technologies that have made it possible to treat disease in unprecedented ways and highlights CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) development of protein-based angiogenesis as part of a group of therapies that 'form a vision for the next generation of drugs,'" Clark added. "Angiogenesis refers to the growth of new blood vessels that may help those suffering from coronary heart disease by increasing blood flow associated with the disease."
The article, titled "Tomorrow's Drugs," can be viewed at www.cvbt.com.
CVBT is a biopharmaceutical company developing formulations of its active pharmaceutical ingredient (API), Fibroblast Growth Factor-1, to treat a number of diseases characterized by inadequate blood flow to a tissue or organ. In addition to its cardiac clinical trial of FGF-1 (CVBT-141A) in Limited-Option Heart Patients, the Company is conducting FDA-authorized clinical trials of FGF-1 (CVBT-141B) for dermal wound healing in diabetics, and peripheral artery disease (CVBT-141C).
An informational report featuring CardioVascular BioTherapeutics is available at: http://stockupticks.com/profiles/2-2-06.html.
The report "The Silver Tsunami, Baby Boomers and Biotech Breakthroughs" is also available at www.SmallCapSentinel.com and contains data and information of interest to cardiac-related companies including CVBT, Boston Scientific Corporation (NYSE:BSX), Medtronic, Inc., (NYSE:MDT), and Cardium Therapeutics, Inc. (AMEX:CXM).
For ongoing information regarding the aforementioned and other emergent public companies please register at:
http://stockupticks.com/register.html
To be featured in SmallCap Sentinel contact us at the number below.
Statements herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP isn't an investment advisor and this report isn't investment advice. MP has been paid $19,200 by CVBT for preparation and distribution of this report and other advertising. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies.
The SmallCap Sentinel logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3664